Cambridge Innovation Capital

Cambridge Innovation Capital is a Cambridge, United Kingdom-based venture capital firm focused exclusively on deep technology, life science, health technology, and enterprise software companies that originate from or have strong connections to the University of Cambridge research ecosystem, providing patient growth capital to help world-class academic research translate into global commercial companies. The firm was established in 2013 with the support of the University of Cambridge and Johnson and Johnson, and has maintained a unique partnership with the University that gives it privileged early access to breakthrough technologies and scientific founders emerging from Cambridge laboratories. Cambridge Innovation Capital invests from seed through growth stages with initial checks typically from $2 million to $15 million, and focuses on companies in therapeutic medicine, medical devices, diagnostics, AI-enabled healthcare, quantum computing, materials science, and enterprise software where the technology has genuine and defensible breakthrough characteristics. The Cambridge ecosystem has produced multiple globally significant deep technology companies in recent years, and Cambridge Innovation Capital is positioned as the primary institutional early-stage backer for companies emerging from this world-class research environment. Portfolio companies include CMR Surgical, which developed the Versius robotic surgery system and is one of the UK's most valuable private life science companies; Healx, which applies AI to rare disease drug discovery; and Bicycle Therapeutics, a clinical-stage biopharmaceutical company that is publicly listed on Nasdaq. Beyond its original investments in CMR Surgical, Healx, and Bicycle Therapeutics, the portfolio includes additional Cambridge-originating companies in therapeutics, diagnostics, and enterprise deep tech.